NCT00360737View on ClinicalTrials.gov

Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

April 30, 2010

Conditions
Healthy
Interventions
BIOLOGICAL

Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)

Biological/Vaccine NP-018 (heptavalent equine-derived botulinum antitoxin) is prepared from pooled plasma obtained from horses that have been immunized against one of seven botulinum antitoxins (A-G). .

Trial Locations (1)

85044

MDS Pharma Services, Phoenix

Sponsors
All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

Emergent BioSolutions

INDUSTRY